Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 27 Apr 2023
In the second week of life, 83 percent of newborns who were fed formula milk had Clostridium difficile and Clostridium perfringens, but by the end of the third week, all infants had these infections.
Read Full NewsIn patients with newly diagnosed fibromyalgia who have prominent symptoms of anxiety and depression, remission of depression — not pain reduction alone — determines clinical improvement.
Most ADHD coaches do not have behavioral health training, a study finds, but experts say peer support can help people navigate living with the condition.
In the long term, stereotactic body radiotherapy carries a lower risk for biochemical failure vs high-dose rate brachytherapy for men with intermediate-risk prostate cancer.
1.
FDA Expands Approval of Osimertinib in Lung Cancer
2.
An inoperable locally advanced NSCLC trial dubbed "Practice Changing".
3.
Alkem introduces cetuximab under the trade name Cetuxa in India.
4.
Implant-based reconstruction linked to increased risk of breast lymphomas
5.
Aspirin for CRC Risk Reduction May Benefit Unhealthy People Most
1.
Uncovering the Mysteries of the RDW Blood Test
2.
Understanding SVR Normal Range: A Guide to Achieving Optimal Health
3.
An Overview Of Leukemia Cutis: What It Is And How To Treat It
4.
The Pros and Cons of Using Cyclophosphamide in Cancer Treatment
5.
Neoadjuvant Radiotherapy & Endocrine Therapy in ER+ Breast Cancer Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI
2.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session
3.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV
4.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
5.
A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge